TAmiRNA bringing senescence biomarker insights to Longevity Therapeutics Summit

Researchers from biotech innovator TAmiRNA will use the Longevity Therapeutics Summit in California to present latest advances in the development of circulating microRNA markers to diagnose and monitor senescence.

TAmiRNA is a leading partner of the recently founded event, now in its second year.

Diagnosing senescence burden

TAmiRNA founder and CEO, Dr. Matthias Hackl, will deliver a presentation on newly-developed senomiR® proprietary circulating microRNA signatures for diagnosis of senescence burden and treatment response monitoring.

Dr. Hackl’s address will form part of the Cellular Pathways Developments session on Day One of the Summit (January 28, 12:20hrs).

Novel senomiR biomarkers

“We believe these developments will be of key interest to biotech and pharma companies as well as universities and clinical research groups participating in pre-clinical as well as clinical studies,” said Dr. Hackl.

“MicroRNAs are tissue-specific regulators of gene expression and cell function. Cells that are becoming senescent are known to exhibit an altered miRNA profile and secretory phenotype. The analysis of senescence-associated microRNAs (senomiRs) in blood provides a promising novel readout of senescence load in an organism,” explained Dr. Moritz Weigl, who works on TAmiRNA’s senomiR® team.

“Blood-levels of senomiR® show particularly strong associations with senescence load in skin, kidney and muscle,” Dr. Weigl noted.

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.

TAmiRNA is developing biofluid-based diagnostic tests based on circulating microRNAs and providing contract research services for discovery and validation of RNA-based biomarkers. The focus of TAmiRNA are age-associated diseases, where senescence plays a major role for onset and progression of disease. TAmiRNA has developed senomiR®, a proprietary microRNA signature intended for diagnosis of senescence burden and treatment response monitoring, and is looking to establish partnerships for development of disease/drug-specific applications of its biomarker platform.

More information available at: www.tamirna.com

About Longevity Therapeutics Summit

Founded in 2019, the Longevity Therapeutics Summit is dedicated to exploring latest advances in the understanding of the underlying biology and mechanisms of aging, ground-breaking research and technology and the targeting of aging pathways to prevent, reverse or delay the onset of age-related conditions, and consequently improve healthy lifespan.

Longevity Therapeutics 2020 is a three-day event opening January 28 at the Holiday Inn Golden Gateway Hotel in San Francisco, California.

The 2nd Longevity Therapeutics Summit will once again bring together 80+ leading experts in aging-related research, including biotechs, pharma, academics and investors, who are committed to serving worldwide population with innovative drugs to prevent, delay and treat age-related conditions.

The event is organized by Hanson Wade with further information at: https://longevity-therapeutics.com/


Click on TAmiRNA at Longevity Therapeutics 2020 for other information.
Click on TAmiRNA to contact the company directly.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.